GeneTex
  • Country / Location Selection

United States (US)
Breast Cancer Tumor Markers

Breast Cancer Tumor Markers

Breast Cancer Tumor Markers

Breast cancer is the most common malignancy among women, but also occurs in men (1). Risk factors include female gender, age, family history, smoking, metabolic syndrome and genetic predisposition, among others. There are various types of breast cancer, with ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC) being the most common. Triple-negative breast cancer, with malignant cells having low or absent HER2, estrogen receptor, and progesterone receptor expression, accounts for 10-15% of cases and is particularly aggressive.

See All Antibodies for Breast Cancer Markers

 

 
 

HER2, also known as proto-oncogene Neu or ERBB2, is a member of the human epidermal growth factor receptor family of tyrosine kinases. GeneTex’s HER2 / ERBB2 antibody (GTX100509) specifically detects HER2 protein by WB and generates the expected expression pattern in HER2-positive breast tumor sections by IHC-P (Figure 1).

Her2 / ErbB2 antibody


Figure 1. GeneTex's HER2 / ERBB2 antibody (GTX100509) is sensitive and specific for HER2 expression (left). A side-by-side comparison between this antibody and a competitor’s reagent was performed for IHC-P at 1:500 and 1:100 dilutions, respectively (right).

 

 
 

Estrogen Receptor Alpha (ERα) and Beta (ERβ) have distinct cellular distributions, regulate separate sets of genes, and oppose each other in breast cancer (2). ERα and ERβ have been extensively studied and targeted for the development of therapeutics against hormone-positive breast cancer. GeneTex’s Estrogen Receptor Alpha antibody [1F3] (GTX70171) is a mouse monoclonal antibody whose sensitivity and specificity have been stringently validated by GeneTex and in multiple publications. The Estrogen Receptor Beta antibody [14C8] (GTX70174) is one of the most commonly used reagents to detect ERβ with more than one hundred citations (Figure 2).


Figure 2. GeneTex’s Estrogen Receptor Alpha antibody [1F3] (GTX70171) (left) and Estrogen Receptor Beta antibody [14C8] (GTX70174) (right) have superior specificity and are well validated in multiple publications.

 

 
 

The progesterone receptor (PR) is a well-known estrogen receptor (ER) target gene that is expressed in over two-thirds of ER-positive breast cancers (3). It acts as a transcriptional regulator and activator of signal transduction pathways (i.e., MAPK, PI3K/Akt, and c-Src) that can drive proliferative signaling in breast cancer cells (4). GeneTex’s Progesterone Receptor antibody [N1], N-term (GTX116051) was developed for IHC-P. It demonstrates distinct staining differences on PR-negative and PR-positive breast tumor tissue sections (Figure 3).

Progesterone Receptor antibody [N1], N-term


Figure 3. GeneTex’s Progesterone Receptor antibody [N1], N-term (GTX116051) gives negative staining of PR-negative breast cancer tissue sections (left) and robust nuclear staining in PR-positive sections (right).

 

 
 

Some inherited mutations in BRCA1 are established drivers of breast cancer. GeneTex’s BRCA1 antibody [17F8] (GTX70111) is a highly cited monoclonal antibody validated for various applications including WB, ICC/IF, IHC-P, IP, ELISA, and ChIP (Figure 4).

BRCA1 antibody [17F8] - ChIP grade


Figure 4. GeneTex’s BRCA1 antibody [17F8] (GTX70111) was validated for WB using knockout cell lysate (left) and for IHC on carcinoma tissue sections (right).

 

Table: Markers associated with breast cancer

Cat. No. Product Name Reactivity Applications
GTX70111 BRCA1 antibody [17F8] - ChIP grade Hu, Ms WB, ICC/IF, IHC-P, IP, ELISA, ChIP assay, IHC
GTX70123 BRCA2 antibody [5F6] Hu WB, IHC-P, IHC-Fr
GTX70171 Estrogen Receptor alpha antibody [1F3] Hu, Rb WB, IHC-Fr, FACS, IP
GTX70174 Estrogen Receptor beta antibody [14C8] Hu, Ms, Mk WB, ICC/IF, IHC-P, IHC-Fr, FACS, Dot, ChIP assay, IHC
GTX116051 Progesterone Receptor antibody [N1], N-term Hu ICC/IF, IHC-P
GTX100509 Her2 / ErbB2 antibody Hu WB, IHC-P
GTX79597 uPA antibody Hu, Ms, Rat WB, IHC-P, IHC-Fr, ELISA
GTX60537 PAI-1 antibody [1D5] Hu, Ms WB, IHC-P, FACS, ELISA
GTX20697 CA125 antibody [OV185:1] Hu IHC-P
GTX17254 CEA antibody [Col-1] Hu IHC-P
GTX70214 p53 antibody [DO1] Hu, Ms WB, ICC/IF, IHC-P, IHC-Fr, FACS, IP, ELISA
GTX16667 Ki67 antibody [SP6] Hu, Ms, Rat, Chk WB, ICC/IF, IHC-P, IHC-Fr, FACS, IHC

 

References

  1. Lancet. 2017 Mar 18;389(10074):1134-1150.
  2. Endocr Relat Cancer. 2002 Mar;9(1):1-13.
  3. J Clin Oncol. 2007 Oct 20;25(30):4772-8.
  4. Expert Rev Endocrinol Metab. 2011 May 1;6(3):359-369.